Company Performance - Forge Global Holdings, Inc. reported a quarterly loss of $1.29 per share, which was better than the Zacks Consensus Estimate of a loss of $1.34, and an improvement from a loss of $1.50 per share a year ago, representing an earnings surprise of 3.73% [1] - The company posted revenues of $25.3 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.27%, and showing an increase from year-ago revenues of $19.24 million [2] - Over the last four quarters, Forge Global has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Forge Global shares have declined approximately 13.5% since the beginning of the year, compared to a decline of 4.7% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$1.03 on revenues of $23.22 million, and for the current fiscal year, it is -$4.27 on revenues of $98.57 million [7] Industry Outlook - The Financial - Miscellaneous Services industry, to which Forge Global belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Forge Global's stock performance [5]

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. What's Next for Apellis Pharmaceuticals? While Apellis Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measu ...

分组1 - MarketAxess reported quarterly earnings of $1.87 per share, exceeding the Zacks Consensus Estimate of $1.82 per share, but down from $1.92 per share a year ago, representing an earnings surprise of 2.75% [1] - The company posted revenues of $208.58 million for the quarter, missing the Zacks Consensus Estimate by 0.97%, and down from $210.32 million year-over-year [2] - Over the last four quarters, MarketAxess has surpassed consensus EPS estimates four times but has only topped consensus revenue estimates once [2] 分组2 - The stock has gained approximately 1.3% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is $1.91 on revenues of $214.96 million, and for the current fiscal year, it is $7.59 on revenues of $870.21 million [7] - The Zacks Industry Rank for Financial - Investment Bank is currently in the bottom 24% of over 250 Zacks industries, indicating potential challenges for the sector [8]

Company Performance - Turning Point Brands (TPB) reported quarterly earnings of $0.91 per share, exceeding the Zacks Consensus Estimate of $0.75 per share, and up from $0.80 per share a year ago, representing an earnings surprise of 21.33% [1] - The company posted revenues of $106.44 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 11.92%, compared to $97.06 million in the same quarter last year [2] - Over the last four quarters, Turning Point Brands has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Turning Point Brands shares have increased approximately 8% since the beginning of the year, while the S&P 500 has declined by 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is $0.91 on revenues of $106.55 million, and for the current fiscal year, it is $3.42 on revenues of $425.4 million [7] Industry Outlook - The Tobacco industry, to which Turning Point Brands belongs, is currently ranked in the top 9% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 19.35%. A quarter ago, it was expected that this company would post earnings of $0.15 per share when it actually produced earnings of $0.14, delivering a surprise of -6.67%.Over the last four quar ...

Group 1: Earnings Performance - LifeStance Health Group (LFST) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.04, and improved from a loss of $0.06 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $332.97 million for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.08%, compared to year-ago revenues of $300.44 million [2] - Over the last four quarters, LifeStance Health has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - LifeStance Health shares have declined approximately 11.1% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.03 on revenues of $351.71 million, and -$0.10 on revenues of $1.42 billion for the current fiscal year [7] Group 3: Industry Context - The Medical - Outpatient and Home Healthcare industry, to which LifeStance Health belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5] - The favorable estimate revisions trend for LifeStance Health has resulted in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

分组1 - Keros Therapeutics reported quarterly earnings of $3.62 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.01 per share, and showing an improvement from a loss of $1.21 per share a year ago, resulting in an earnings surprise of 36,300% [1] - The company posted revenues of $211.25 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 149.64%, compared to revenues of $0.08 million in the same quarter last year [2] - Keros Therapeutics shares have declined approximately 8.1% since the beginning of the year, while the S&P 500 has decreased by 3.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$1.02 on revenues of $8.28 million, and for the current fiscal year, it is -$3.46 on revenues of $100.68 million [7] - The Medical - Biomedical and Genetics industry, to which Keros Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - CuriosityStream Inc. reported quarterly earnings of $0.01 per share, surpassing the Zacks Consensus Estimate of a loss of $0.01 per share, marking a significant improvement from a loss of $0.09 per share a year ago, indicating a 200% earnings surprise [1] Financial Performance - The company achieved revenues of $15.09 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.36%, compared to $12 million in revenues from the same quarter last year [2] - Over the last four quarters, CuriosityStream has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - CuriosityStream shares have increased approximately 115% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, with current consensus EPS estimates for the upcoming quarter at -$0.02 on revenues of $14.2 million, and -$0.05 on revenues of $61.9 million for the current fiscal year [4][7] - The estimate revisions trend for CuriosityStream is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Film and Television Production and Distribution industry, to which CuriosityStream belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

While Clover Health Investments has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Clover Health Investments, Corp. (CLOV) came out with quarterly ear ...

Core Insights - ProAssurance reported quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.19 per share, but showing an improvement from $0.08 per share a year ago, resulting in an earnings surprise of -31.58% [1] - The company posted revenues of $269.76 million for the quarter, which was 0.33% below the Zacks Consensus Estimate and down from $282 million year-over-year [2] - ProAssurance shares have increased by approximately 44.4% since the beginning of the year, contrasting with a -3.9% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.20, with expected revenues of $270.08 million, and for the current fiscal year, the EPS estimate is $0.92 on revenues of $1.08 billion [7] - The estimate revisions trend for ProAssurance is currently favorable, leading to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Insurance - Property and Casualty industry is ranked in the top 17% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]